Int J Gynecol Pathol. 2022 Nov 1;41(6):541-551. doi: 10.1097/PGP.0000000000000841. Epub 2021 Dec 15.
Determining the replicative DNA polymerase epsilon ( POLE) mutation status in endometrial carcinomas (ECs) has important clinical implications given that the majority of "ultramutated" tumors harboring pathogenic exonuclease domain mutations in POLE ( POLE mut) have a favorable prognosis, even among high-grade histotypes. Currently, there are no specific morphologic or immunophenotypic features that allow accurate detection of POLE mut tumors without molecular testing. Consequently, identifying POLE mut tumors has been challenging without employing costly and/or time-consuming DNA sequencing approaches. Here we developed a novel SNaPshot assay to facilitate routine and efficient POLE mutation testing in EC. The SNaPshot assay interrogates 15 nucleotide sites within exons 9, 11, 13, and 14 encoding the POLE exonuclease domain. The variant sites were selected based on recurrence, evidence of functional impact, association with high tumor mutation burden and/or detection in EC clinical outcome studies. Based on the pathogenic somatic variants reported in the literature, the assay is predicted to have a clinical sensitivity of 90% to 95% for ECs. Validation studies showed 100% specificity and sensitivity for the variants covered, with expected genotypic results for both the positive (n=11) and negative (n=20) patient controls on multiple repeat tests and dilution series. Analytic sensitivity was conservatively approximated at a 10% variant allele fraction (VAF), with documented detection as low as 5% VAF. As expected, the SNaPshot assay demonstrated greater sensitivity than Sanger sequencing for VAFs below 20%, an important characteristic for somatic mutation detection. Here we have developed and validated the first SNaPshot assay to detect hotspot POLE mutations. While next-generation sequencing and Sanger sequencing-based approaches have also been used to detect POLE mutations, a SNaPshot approach provides useful balance of analytical sensitivity, cost-effectiveness, and efficiency in a high-volume case load setting.
确定子宫内膜癌(EC)中复制 DNA 聚合酶ε(POLE)突变状态具有重要的临床意义,因为大多数携带 POLE 外切酶结构域致病性突变的“超突变”肿瘤(POLEmut)具有良好的预后,即使在高级别组织学类型中也是如此。目前,没有特定的形态学或免疫表型特征可以在不进行分子检测的情况下准确检测 POLEmut 肿瘤。因此,如果不采用昂贵且/或耗时的 DNA 测序方法,识别 POLEmut 肿瘤具有挑战性。在这里,我们开发了一种新的 SNaPshot 检测方法,以促进 EC 中常规和高效的 POLE 突变检测。SNaPshot 检测方法检测编码 POLE 外切酶结构域的外显子 9、11、13 和 14 中的 15 个核苷酸位点。变异位点是基于复发、功能影响证据、与高肿瘤突变负担的相关性和/或在 EC 临床结果研究中的检测选择的。基于文献中报道的致病性体细胞变体,该检测方法预计对 EC 的临床敏感性为 90%至 95%。验证研究表明,对于涵盖的变体,该检测方法具有 100%的特异性和敏感性,对于多个重复测试和稀释系列的阳性(n=11)和阴性(n=20)患者对照,都得到了预期的基因型结果。分析灵敏度保守地估计为 10%的变异等位基因分数(VAF),记录的检测低至 5%的 VAF。正如预期的那样,SNaPshot 检测方法在 VAF 低于 20%时比 Sanger 测序具有更高的灵敏度,这是体细胞突变检测的一个重要特征。在这里,我们开发并验证了第一个用于检测热点 POLE 突变的 SNaPshot 检测方法。虽然下一代测序和基于 Sanger 测序的方法也已用于检测 POLE 突变,但 SNaPshot 方法在大容量病例量设置中提供了有用的分析灵敏度、成本效益和效率之间的平衡。